Aquestive Therapeutics to Participate in Upcoming Investor Conferences
Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company committed to improving patient lives through innovative science and delivery technologies, is thrilled to announce its involvement in two major investor conferences taking place in September.
Details of the Conferences
The management team at Aquestive Therapeutics will be presenting at the following events:
- H.C. Wainwright 26th Annual Global Investor Conference: Scheduled for 8:30 am ET on a specified date, this presentation will also include opportunities for investor meetings.
- Lake Street BIG8 Conference: This event will similarly provide a platform for the management to engage in discussions with investors.
Webcast Access for Investors
For those who cannot attend in person, a webcast of the H.C. Wainwright presentation will be available on the "Events and Presentation" page within the Investors section of the Company’s website. A replay will be accessible for 30 days following the live presentation, allowing interested individuals to catch up on the insights shared during the event.
About Aquestive Therapeutics
Aquestive stands out in the pharmaceutical industry, focusing on the development of orally administered products designed to effectively deliver complex molecules. This approach offers innovative alternatives to traditional, invasive therapies that can often be inconvenient for patients.
Commercial Successes
Aquestive has successfully commercialized five products, which are distributed through licensing agreements across various regions worldwide. The company continues to be the exclusive manufacturer of these products, highlighting its essential role in the supply chain.
Collaborative Initiatives
To broaden its innovative capabilities, Aquestive collaborates with other pharmaceutical companies to bring new molecules to market. By utilizing proprietary technologies, such as the renowned PharmFilm®, and leveraging extensive drug development expertise, the Company continuously seeks to improve treatment options for patients.
Future Product Innovations
Aquestive is currently advancing a late-stage product candidate aimed at treating severe allergic reactions, including anaphylaxis. Additionally, the company is investigating an early-stage prodrug topical gel product candidate for various dermatological conditions. These initiatives reflect a dedication to expanding treatment options across a range of health challenges.
Contact for Investor Inquiries
Those interested in learning more about the company or its upcoming presentations can directly reach out to their investor relations team. The contact details are as follows:
ICR Westwicke
Stephanie Carrington
Email: stephanie.carrington@westwicke.com
Phone: 646-277-1282
Frequently Asked Questions
What is the purpose of the upcoming investor conferences?
The conferences provide an opportunity for Aquestive Therapeutics to showcase their latest innovations and engage with investors to discuss company developments and future plans.
Who can attend the presentations?
Investors, analysts, and other stakeholders interested in learning more about Aquestive Therapeutics are welcome to attend the presentations and meetings.
Will recordings of the presentations be available?
Yes, webcasts of the presentations will be hosted on the Company’s website, with replays available for 30 days after the events.
What types of products is Aquestive working on?
Aquestive is dedicated to developing innovative orally administered medications that serve as alternatives to traditional therapies, including products for allergic reactions and dermatological conditions.
How can investors reach out to Aquestive for more information?
Investors can contact the investor relations team via email at stephanie.carrington@westwicke.com or by calling 646-277-1282.
